• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Fennec Pharmaceuticals Inc.

    4/28/26 4:15:30 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FENC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    FENNEC PHARMACEUTICALS INC.

    (Name of Issuer)


    Common Shares, no par value

    (Title of Class of Securities)




    31447P100

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    31447P100


    1Names of Reporting Persons

    Orin Hirschman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,981,501.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,981,501.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,981,501.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.7 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP Number(s):
    31447P100


    1Names of Reporting Persons

    AIGH Capital Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,981,501.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,981,501.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,981,501.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.7 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    FENNEC PHARMACEUTICALS INC.
    (b)Address of issuer's principal executive offices:

    PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, NC, 27709
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the "Act"): (i) AIGH Capital Management, LLC, a Maryland limited liability company ("AIGH CM"), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P., and WVP Emerging Manger Onshore Fund, LLC - AIGH Series. (ii) AIGH Investment Partners, L.L.C., a Delaware limited liability company ("AIGH LLC";), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it; (iii) Mr. Orin Hirschman ("Mr. Hirschman"), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock (as defined in Item 2(d) below) indirectly held through AIGH CM, directly by AIGH LLC and Mr. Hirschman and his family directly. AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
    (b)Address or principal business office or, if none, residence:

    The principal office and business address of AIGH Capital Management LLC, AIGH Investment Partners LLC, and Mr.Hirschman is: 6006 Berkeley Avenue, Baltimore MD 21209
    (c)Citizenship:

    See Item 2(a) above and Item 4 of each cover page.
    (d)Title of class of securities:

    Common Shares, no par value
    (e)CUSIP Number(s):

    31447P100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,981,501
    (b)Percent of class:

    5.7  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1,981,501

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    1,981,501

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Orin Hirschman
     
    Signature:/s/ Orin Hirschman
    Name/Title:Orin Hirschman
    Date:04/28/2026
     
    AIGH Capital Management LLC
     
    Signature:/s/ Orin Hirschman
    Name/Title:Orin Hirschman, Managing Member
    Date:04/28/2026
    Get the next $FENC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FENC

    DatePrice TargetRatingAnalyst
    2/12/2026$16.00Buy
    B. Riley Securities
    1/9/2026Overweight
    Piper Sandler
    11/22/2022$9.00 → $12.00Neutral → Overweight
    Cantor Fitzgerald
    9/7/2022$11.00Overweight
    CapitalOne
    8/8/2022$14.00Buy
    Craig Hallum
    More analyst ratings

    $FENC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

    ~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows Administration of PEDMARK® Approximately Six Hours After Cisplatin Can Be Safe & Easily Integrated into Patient Care and Does Not Compromise Cisplatin's Established Antitumor Activity ~ RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as

    5/21/26 6:01:27 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of stock option awards ("Stock Options") to purchase an aggregate of 50,000 of the Company's common shares to three new non-executive employees of the Company with a grant date of May 18, 2026 under the Company's 2026 Equity Inducement Plan (the "Inducement Plan"). The Stock Options consist of incentive stock options to purchase an aggregate of 49,141 shares and nonqualified stock options to pur

    5/18/26 4:30:00 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

    ~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK® in Adolescent and Young Adult (AYA) and Adult Patients with Head and Neck and Testicular Cancers ~ ~ Four Abstracts Evaluating PEDMARK® will be Included in the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Program ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a sp

    5/14/26 6:30:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hackman Jeffrey S. bought $104,602 worth of shares (15,000 units at $6.97) (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    5/19/25 5:42:21 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Andrade Robert bought 12,500 shares, increasing direct ownership by 14% to 104,271 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    4/3/24 5:00:11 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raykov Rosty bought 29,167 shares, increasing direct ownership by 10% to 316,638 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    4/3/24 4:55:10 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    SEC Filings

    View All

    Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

    5/22/26 4:05:17 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

    5/18/26 5:12:12 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Fennec Pharmaceuticals Inc.

    10-Q - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

    5/14/26 4:24:42 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Raykov Rosty was granted 2,778 shares, exercised 15,597 shares at a strike of $2.45 and sold $93,766 worth of shares (9,747 units at $9.62) as part of a pre-agreed trading plan, increasing direct ownership by 7% to 130,079 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    6/2/26 4:05:28 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.65% to 24,176 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    6/1/26 4:05:19 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Hackman Jeffrey S. was granted 1,159 shares, increasing direct ownership by 2% to 62,825 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    6/1/26 4:05:07 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PEDMARK issued to FENNEC PHARMACEUTICALS INC

    Submission status for FENNEC PHARMACEUTICALS INC's drug PEDMARK (ORIG-1) with active ingredient SODIUM THIOSULFATE has changed to 'Approval' on 09/20/2022. Application Category: NDA, Application Number: 212937, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/20/22 3:54:04 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Fennec Pharmaceuticals with a new price target

    B. Riley Securities initiated coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $16.00

    2/12/26 7:24:33 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Fennec Pharmaceuticals

    Piper Sandler initiated coverage of Fennec Pharmaceuticals with a rating of Overweight

    1/9/26 9:04:54 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Fennec Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously

    11/22/22 9:21:25 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fennec Pharmaceuticals Inc.

    SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

    11/12/24 7:38:18 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

    SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

    6/27/24 4:43:33 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

    SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

    2/14/24 10:47:17 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Financials

    Live finance-specific insights

    View All

    Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

    ~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK® in Adolescent and Young Adult (AYA) and Adult Patients with Head and Neck and Testicular Cancers ~ ~ Four Abstracts Evaluating PEDMARK® will be Included in the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Program ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a sp

    5/14/26 6:30:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

    RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Thursday, May 14, 2026Time: 8:30 a.m. Eastern TimeWebcast Link: https://edge.media-server.com/mmc/p/2iptdco4Participant Link: https://register-conf.media-server.com/register/BIaa4b518aeb974d02873eccf8f56d92f3

    5/7/26 6:36:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    ~ Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~ ~ Executed on 2025 Clinical Data Strategy to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations Through Independent, Institution-Led Research ~ ~ Achieved Record Performance with All-Time High Patient Enrollments and Conversion Rates in Q4 2025, Reflecting Strong Field Execution ~ ~ Completed Oversubscribed $42 Million Equity Offerings with Participation from New and Existing Investors ~ ~ Announced Positive Toplin

    3/24/26 7:00:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Leadership Updates

    Live Leadership Updates

    View All

    Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

    ~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec's strategic direction for operational success in the expansion of PEDMARK® use in c

    8/5/24 6:26:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care